This information collection supports
implementation of the Food and Drug Administration (FDA, us or we)
Prescription Drug User Fee program. Under the prescription drug
user fee provisions of the Federal Food, Drug, and Cosmetic Act
(the FD&C Act) (sections 735 and 736 (21 U.S.C. 379g and
379h)), as amended, we have the authority to assess and collect
user fees for certain new drug applications (NDAs) and new
biologics license applications (BLAs)
US Code:
21
USC 379 Name of Law: Federal Food Drug and Cosmetic Act
The information collection
reflects adjustments. We have decreased the burden estimate by
1,724 hours and 3,447 responses to reflect a decrease in
submissions. This is discussed more fully in our supporting
statement at Question 15.
$14,934
No
No
No
No
No
No
Uncollected
Domini Bean 301 796-5733
domini.bean@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.